Home News Weather Finance Travel Maps Movies Lottery Horoscopes Games
 SECTION: DISEASE, MEDICINE, HEALTH CARE RESEARCH
Search The Web:
DOMAIN NAMES
AS LOW AS $2.99 / YR.
Health Officials Cancel HIV Vaccine Trial
Friday, 18-Jul-2008 1:14PM United Press International
USTINET NEWS

 » Front Page

 » Top Stories

 » U.S.

 » World

 » Politics

 » Business

 » Sports

 » Health

 » Tech/Science

    Aerospace & NASA

    Computers

    Electronics

    Environment

    Nuclear

    Science

    Telecomm

 » Living/Entertainment

 » Off Beat Stories

 » News Photos

 » Weather


Special Editions

 » Iraq & Conflict

 » Israel/Palestine

 » Crimes & Laws


MultiMedia

 » Interactive Features

 » News Photos


POLL: Your Opinion

 » What Do You Think




BETHESDA, Md., July 18 (UPI) -- Health officials canceled a U.S. human trial of a human immunodeficiency virus vaccine, saying the size and scope of the proposed trial was too large.

SAVE MONEY ON TRAVEL DEALS

"After soliciting and considering broad input from the scientific and HIV advocacy communities, the National Institute of Allergy and Infectious Diseases ... has determined that it will not conduct the HIV vaccine study known as PAVE 100", the National Institutes of Health division said Thursday in a news release.

"However, ... NIAID will entertain a proposal for an alternative study with one specific goal: to determine if the vaccine regimen significantly lowers viral load -- the amount of HIV in the blood of vaccinated individuals who may later become infected with HIV", the virus that causes AIDS, the agency said.

PAVE, the Partnership for AIDS Vaccine Evaluation, is a consortium of U.S. government agencies and government-funded organizations involved in developing and evaluating experimental HIV vaccines that might not be developed by pharmaceutical companies or institutions on their own.

The trial was supposed to have begun enrolling 8,500 volunteers last October to receive the vaccine, The New York Times reported. It was delayed after a test of a similar vaccine made by Merck failed in its two main goals: infection prevention and lowing the amount of HIV in the blood in volunteers who became infected.

Also, findings among the 3,000 participants in nine countries where the Merck vaccine was tested suggested it might have increased the risk of volunteers of becoming infected with HIV, the Times said.

- - - - - - - - - - - - - - - - - - - -
Related News Topics:

HIV and AIDS research, politics
Top science, technical and computer stories
Disease, medicine, health care research
Miscellaneous science and technology stories
Disease, medicine, aids, health care research

 BREAKING STORIES

Official: Russia has no melamine victims

N. Korea: Kim Jong Il makes troop visit

Plastic surgery makes advances in wartime

New law puts mental, physical ills on par

Cervical cancer shot gains acceptance

Study: Ginkgo can prevent stroke damage

WHO probes deadly mystery illness

Claim: Magic Johnson 'faked' AIDS

Exercise intervention helps with arthritis

WHO: Mental health stigma unfair

Bird flu survival tied to hands-on therapy

TV star to wed after getting cancer news

NSAIDs linked to lower breast cancer risk

Kids' asthma diagnosis can be a challenge

Herb may help curb bad breath

New procedure to correct sagging breasts

Why pizza may cause women pain, urination

Cocoa powder high in anti-oxidants

Genetic code of malaria parasite sequenced

Cuban exiles irked by aid cutoff rule

Home News Weather Finance Travel Maps Movies Lottery Horoscopes Games
Home :: My Page :: My WebMail :: My Calendar :: My Portfolio :: Chat :: Help Center :: Sign In :: Sign Out

MY.USTI.NET PORTAL  -  © 1996 - 2004 USTINET CORPORATION. ALL RIGHTS RESERVED.
Please see our Privacy Policy, Security Guarantee, Terms of Use for additional information.